Compare Amgen, Inc. (AMGN) vs Quantum Computing Inc (QUBT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Quantum Computing Inc — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Quantum Computing Inc trades at $8.54 (market cap $1.95B). The key difference: Amgen, Inc. is far larger — about 100.6× Quantum Computing Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Quantum Computing Inc pays none. Which is the better fit depends on your goals.
| AMGN | QUBT | |
|---|---|---|
Market Cap | $196.12B | $1.95B |
Sector | Health | Technology |
52-Week High | $388.16 | $24.62 |
52-Week Low | $271.18 | $6.31 |
Enterprise Value | $241.41B | $970.72M |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Quantum Computing Inc. (QUBT) trades at $8.66, down 5.36% today, with a bearish technical outlook but strong analyst support. The company reported a net loss of $18.67 million on minimal revenue of $682,000 in 2025, reflecting high cash burn. Recent strategic acquisitions and a $10 million framework agreement with Planck Dynamics highlight growth initiatives, yet profitability remains distant amid negative margins.
QUBT offers speculative upside with a consensus price target of $24.00 (177% potential), but faces significant execution and funding risks. Investors must weigh long-term quantum technology potential against persistent losses and the need for substantial capital to survive until commercialization, making it suitable only for high-risk portfolios.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Quantum Computing Inc
Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →
